{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:19:33Z","timestamp":1788981573391,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13318-026-01016-y","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T11:17:32Z","timestamp":1782040652000},"page":"587-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toxicity-Tailored Thresholds of Delayed Methotrexate Elimination in Non-Hodgkin Lymphoma: A Population-Based Approach to Therapy Optimization"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6296-4090","authenticated-orcid":false,"given":"Tuan","family":"Fauziah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-9261","authenticated-orcid":false,"given":"Ganesh","family":"Kasinathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9748-6347","authenticated-orcid":false,"given":"Teng Keat","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0592-0645","authenticated-orcid":false,"given":"Mohd","family":"Makmor-Bakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8406-3150","authenticated-orcid":false,"given":"Yi Lin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-4213","authenticated-orcid":false,"given":"Noraida","family":"Mohamed Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6243-6975","authenticated-orcid":false,"given":"Shamin","family":"Mohd Saffian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"issue":"3","key":"1016_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10637-025-01542-7","volume":"43","author":"J Zhou","year":"2025","unstructured":"Zhou J, Xing L, Miao Y, Qin S, Zhang R, Tang H, et al. Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis. Invest New Drugs. 2025;43(3):451\u20139. https:\/\/doi.org\/10.1007\/s10637-025-01542-7.","journal-title":"Invest New Drugs."},{"issue":"8","key":"1016_CR2","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/s41375-025-02658-8","volume":"39","author":"SH Zhao","year":"2025","unstructured":"Zhao SH, Zhu ZM, Yang T, Gao D, Liu LH, Yang W, et al. Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma. Leukemia. 2025;39(8):2035\u20138. https:\/\/doi.org\/10.1038\/s41375-025-02658-8.","journal-title":"Leukemia."},{"issue":"2","key":"1016_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/mph.0000000000002995","volume":"47","author":"E Yalcin Gungoren","year":"2025","unstructured":"Yalcin Gungoren E, Koc B, Zulfikar B. Comparison of Capizzi and high-dose methotrexate approaches in the treatment of pediatric B-cell acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2025;47(2):67\u201373. https:\/\/doi.org\/10.1097\/mph.0000000000002995.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"2","key":"1016_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13318-021-00737-6","volume":"47","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Sun L, Chen X, Zhao L, Wang X, Zhao Z, et al. A systematic review of population pharmacokinetic models of methotrexate. Eur J Drug Metab Pharmacokinet. 2022;47(2):143\u201364. https:\/\/doi.org\/10.1007\/s13318-021-00737-6.","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"1016_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106416","volume":"186","author":"Y Yang","year":"2023","unstructured":"Yang Y, Wang C, Chen Y, Wang X, Jiao Z, Wang Z. External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients. Eur J Pharm Sci. 2023;186:106416. https:\/\/doi.org\/10.1016\/j.ejps.2023.106416.","journal-title":"Eur J Pharm Sci."},{"issue":"10","key":"1016_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00432-024-05945-6","volume":"150","author":"SS Bielack","year":"2024","unstructured":"Bielack SS, Soussain C, Fox CP, Houillier C, Murciano T, Osborne W, et al. A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. J Cancer Res Clin Oncol. 2024;150(10):441. https:\/\/doi.org\/10.1007\/s00432-024-05945-6.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"1","key":"1016_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-022-01356-7","volume":"15","author":"T Chen","year":"2022","unstructured":"Chen T, Liu Y, Wang Y, Chang Q, Wu J, Wang Z, et al. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China. J Hematol Oncol. 2022;15(1):136. https:\/\/doi.org\/10.1186\/s13045-022-01356-7.","journal-title":"J Hematol Oncol."},{"key":"1016_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001401","author":"T Fauziah","year":"2025","unstructured":"Fauziah T, Goh AS, Mohamed Shah N, Makmor-Bakry M, Mohd SS. Delayed elimination concentrations of high-dose methotrexate in adults with hematological malignancies: to standardize or not? A Scoping Review Ther Drug Monit. 2025. https:\/\/doi.org\/10.1097\/FTD.0000000000001401. (Epub ahead of print).","journal-title":"A Scoping Review. Ther Drug Monit."},{"issue":"12","key":"1016_CR9","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/jco.1987.5.12.2017","volume":"5","author":"SP Ackland","year":"1987","unstructured":"Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987;5(12):2017\u201331. https:\/\/doi.org\/10.1200\/jco.1987.5.12.2017.","journal-title":"J Clin Oncol."},{"issue":"3","key":"1016_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00262416","volume":"3","author":"WE Evans","year":"1979","unstructured":"Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate. Cancer Chemother Pharmacol. 1979;3(3):161\u20136. https:\/\/doi.org\/10.1007\/BF00262416.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"12","key":"1016_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/nejm197709222971203","volume":"297","author":"RG Stoller","year":"1977","unstructured":"Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297(12):630\u20134. https:\/\/doi.org\/10.1056\/nejm197709222971203.","journal-title":"N Engl J Med."},{"issue":"2","key":"1016_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00280-024-04694-0","volume":"94","author":"SU Rahmayanti","year":"2024","unstructured":"Rahmayanti SU, Amalia R, Rusdiana T. Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients. Cancer Chemother Pharmacol. 2024;94(2):141\u201355. https:\/\/doi.org\/10.1007\/s00280-024-04694-0.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1016_CR13","doi-asserted-by":"publisher","first-page":"757464","DOI":"10.3389\/fphar.2021.757464","volume":"12","author":"Z Song","year":"2021","unstructured":"Song Z, Hu Y, Liu S, Jiang D, Yi Z, Benjamin MM, et al. The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematological malignancies: a systematic review and meta-analysis. Front Pharmacol. 2021;12:757464. https:\/\/doi.org\/10.3389\/fphar.2021.757464.","journal-title":"Front Pharmacol"},{"issue":"24","key":"1016_CR14","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1200\/jco.2002.11.013","volume":"20","author":"LM DeAngelis","year":"2002","unstructured":"DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10. J Clin Oncol. 2002;20(24):4643\u20138. https:\/\/doi.org\/10.1200\/jco.2002.11.013.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1016_CR15","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1055\/s-0033-1337967","volume":"225","author":"G Henze","year":"2013","unstructured":"Henze G, Stackelberg A, Eckert C. ALL-REZ BFM\u2013the consecutive trials for children with relapsed acute lymphoblastic leukemia. Klin Padiatr. 2013;225(Suppl 1):S73-8. https:\/\/doi.org\/10.1055\/s-0033-1337967.","journal-title":"Klin Padiatr."},{"issue":"6","key":"1016_CR16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/cncr.32606","volume":"126","author":"CR Rausch","year":"2020","unstructured":"Rausch CR, Jabbour EJ, Kantarjian HM, Kadia TM. Optimizing the use of the hyperCVAD regimen: clinical vignettes and practical management. Cancer. 2020;126(6):1152\u201360. https:\/\/doi.org\/10.1002\/cncr.32606.","journal-title":"Cancer"},{"issue":"5","key":"1016_CR17","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","volume":"99","author":"M Yamaguchi","year":"2008","unstructured":"Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia. Cancer Sci. 2008;99(5):1016\u201320. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00768.x.","journal-title":"Cancer Sci"},{"issue":"4","key":"1016_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71806","volume":"15","author":"SA Kim","year":"2026","unstructured":"Kim SA, Kim JS, Lee JY, Lee JH, Eom KY, Park CK, et al. Comparative outcomes of consolidation strategies after R-MVP induction in primary diffuse large B-cell lymphoma of the central nervous system. Cancer Med. 2026;15(4):e71806. https:\/\/doi.org\/10.1002\/cam4.71806.","journal-title":"Cancer Med"},{"issue":"8","key":"1016_CR19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.patrec.2005.10.010","volume":"27","author":"T Fawcett","year":"2006","unstructured":"Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett. 2006;27(8):861\u201374. https:\/\/doi.org\/10.1016\/j.patrec.2005.10.010.","journal-title":"Pattern Recognit Lett"},{"issue":"2","key":"1016_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0305-7372(77)80007-8","volume":"4","author":"WA Bleyer","year":"1977","unstructured":"Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4(2):87\u2013101. https:\/\/doi.org\/10.1016\/s0305-7372(77)80007-8.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"1016_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70176","volume":"13","author":"N Tentoni","year":"2024","unstructured":"Tentoni N, Hwang M, Villanueva G, Combs R, Lowe J, Ramsey LB, et al. Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: a retrospective cohort study. Cancer Med. 2024;13(17):e70176. https:\/\/doi.org\/10.1002\/cam4.70176.","journal-title":"Cancer Med"},{"issue":"7","key":"1016_CR22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/phar.2145","volume":"38","author":"CD Flombaum","year":"2018","unstructured":"Flombaum CD, Liu D, Yan SQ, Chan A, Mathew S, Meyers PA, et al. Management of patients with acute methotrexate nephrotoxicity with high-dose leucovorin. Pharmacotherapy. 2018;38(7):714\u201324. https:\/\/doi.org\/10.1002\/phar.2145.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"1016_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12874-024-02198-2","volume":"24","author":"M Hassanzad","year":"2024","unstructured":"Hassanzad M, Hajian-Tilaki K. Methods of determining optimal cut-point of diagnostic biomarkers with application of clinical data in ROC analysis: an update review. BMC Med Res Methodol. 2024;24(1):84. https:\/\/doi.org\/10.1186\/s12874-024-02198-2.","journal-title":"BMC Med Res Methodol."},{"issue":"9","key":"1016_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221591","volume":"14","author":"N Oosterom","year":"2019","unstructured":"Oosterom N, de Jonge R, Smith DEC, Pieters R, Tissing WJE, Fiocco M, et al. Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia. PLoS One. 2019;14(9):e0221591. https:\/\/doi.org\/10.1371\/journal.pone.0221591.","journal-title":"PLoS One."},{"issue":"9","key":"1016_CR25","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.1007\/s00520-021-06106-y","volume":"29","author":"JN Barreto","year":"2021","unstructured":"Barreto JN, Peterson KT, Barreto EF, Mara KC, Dierkhising RA, Leung N, et al. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate. Support Care Cancer. 2021;29(9):5293\u2013301. https:\/\/doi.org\/10.1007\/s00520-021-06106-y.","journal-title":"Support Care Cancer."},{"issue":"3","key":"1016_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.clml.2023.10.012","volume":"24","author":"A Haran","year":"2024","unstructured":"Haran A, Even-Zohar NG, Haran M, Lebel E, Aumann S, Shaulov A, et al. Impact of folinic acid dosing on efficacy and toxicity of high-dose methotrexate in central nervous system lymphoma. Clin Lymphoma Myeloma Leukemia. 2024;24(3):187-93.e1. https:\/\/doi.org\/10.1016\/j.clml.2023.10.012.","journal-title":"Clin Lymphoma Myeloma Leukemia."},{"key":"1016_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.07.003","volume":"142","author":"JN Van der Beek","year":"2019","unstructured":"Van der Beek JN, Oosterom N, Pieters R, de Jonge R, van den Heuvel-Eibrink MM, Heil SG. The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: a systematic review. Crit Rev Oncol Hematol. 2019;142:1\u20138. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.003.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"2","key":"1016_CR28","first-page":"3","volume":"17","author":"MA Mirza","year":"2023","unstructured":"Mirza MA, Aruna D, Konatam ML. Effect of serum albumin level on high-dose methotrexate induced toxicities in acute lymphoblastic leukemia patients. Int J Health Sci (Qassim). 2023;17(2):3\u20139.","journal-title":"Int J Health Sci (Qassim)."},{"issue":"4","key":"1016_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-021-04305-2","volume":"88","author":"G Pesenti","year":"2021","unstructured":"Pesenti G, Foppoli M, Manca D. A minimal physiologically based pharmacokinetic model for high-dose methotrexate. Cancer Chemother Pharmacol. 2021;88(4):595\u2013606. https:\/\/doi.org\/10.1007\/s00280-021-04305-2.","journal-title":"Cancer Chemother Pharmacol."},{"key":"1016_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.817673","volume":"13","author":"J Mao","year":"2022","unstructured":"Mao J, Li Q, Li P, Qin W, Chen B, Zhong M. Evaluation and application of population pharmacokinetic models for identifying delayed methotrexate elimination in patients with primary central nervous system lymphoma. Front Pharmacol. 2022;13:817673. https:\/\/doi.org\/10.3389\/fphar.2022.817673.","journal-title":"Front Pharmacol."},{"issue":"5","key":"1016_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00280-020-04058-4","volume":"85","author":"L Yang","year":"2020","unstructured":"Yang L, Wu H, de Winter BCM, Sheng CC, Qiu HQ, Cheng Y, et al. Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis. Cancer Chemother Pharmacol. 2020;85(5):881\u201397. https:\/\/doi.org\/10.1007\/s00280-020-04058-4.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"3","key":"1016_CR32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bcp.16096","volume":"91","author":"BS Chan","year":"2025","unstructured":"Chan BS, Bosco AA, Buckley NA. Navigating methotrexate toxicity: examining the therapeutic roles of folinic acid and glucarpidase. Br J Clin Pharmacol. 2025;91(3):628\u201335. https:\/\/doi.org\/10.1111\/bcp.16096.","journal-title":"Br J Clin Pharmacol."},{"issue":"6","key":"1016_CR33","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jcpt.13425","volume":"46","author":"S Urata","year":"2021","unstructured":"Urata S, Yoshikawa N, Saito K, Tazaki T, Ohno R, Takeshima H, et al. Delayed methotrexate elimination in a patient with primary central nervous system lymphoma: a case report. J Clin Pharm Ther. 2021;46(6):1796\u20139. https:\/\/doi.org\/10.1111\/jcpt.13425.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"1016_CR34","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/FTD.0000000000000813","volume":"43","author":"F Gallais","year":"2021","unstructured":"Gallais F, Oberic L, Faguer S, Tavitian S, Lafont T, Marsili S, et al. Body surface area dosing of high-dose methotrexate should be reconsidered, particularly in overweight, adult patients. Ther Drug Monit. 2021;43(3):408\u201315. https:\/\/doi.org\/10.1097\/FTD.0000000000000813.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"1016_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5789","volume":"38","author":"J Huo","year":"2024","unstructured":"Huo J, Zhang B, Zhang D, Zhu B, Zhao Z, Mei S. An ultrahigh-performance liquid chromatography-tandem mass spectrometry method for quantification of methotrexate and 7-hydroxy-methotrexate and application for therapeutic drug monitoring in patients with central nervous system lymphoma. Biomed Chromatogr. 2024;38(2):e5789. https:\/\/doi.org\/10.1002\/bmc.5789.","journal-title":"Biomed Chromatogr"},{"key":"1016_CR36","doi-asserted-by":"publisher","first-page":"7719","DOI":"10.12659\/MSM.912999","volume":"24","author":"Y Yang","year":"2018","unstructured":"Yang Y, Wang X, Tian J, Wang Z. Renal function and plasma methotrexate concentrations predict toxicities in adults receiving high-dose methotrexate. Med Sci Monit. 2018;24:7719\u201326. https:\/\/doi.org\/10.12659\/MSM.912999.","journal-title":"Med Sci Monit."},{"issue":"10","key":"1016_CR37","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00277-010-0965-6","volume":"89","author":"Y Kanbayashi","year":"2010","unstructured":"Kanbayashi Y, Nomura K, Okamoto K, Matsumoto Y, Horiike S, Takagi T, et al. Statistical examination to determine whether only 48-h value for serum concentration during high-dose methotrexate therapy is a predictor for clinical adverse events using ordered logistic regression analysis. Ann Hematol. 2010;89(10):965\u20139. https:\/\/doi.org\/10.1007\/s00277-010-0965-6.","journal-title":"Ann Hematol."},{"issue":"5","key":"1016_CR38","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1111\/bcp.15134","volume":"88","author":"Z Song","year":"2022","unstructured":"Song Z, Hu Y, Liu S, Wang G, Zhai S, Zhang X, et al. Medication therapy of high-dose methotrexate: an evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Br J Clin Pharmacol. 2022;88(5):2456\u201372. https:\/\/doi.org\/10.1111\/bcp.15134.","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"1016_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2018","unstructured":"Ramsey LB, Balis FM, O\u2019Brien MM, Schmiegelow K, Pauley JL, Bleyer A, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist. 2018;23(1):52\u201361. https:\/\/doi.org\/10.1634\/theoncologist.2017-0243.","journal-title":"Oncologist."},{"issue":"7","key":"1016_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31744","volume":"72","author":"ZL Taylor","year":"2025","unstructured":"Taylor ZL, Miller TP, Board SG, Poweleit EA, Chavana A, Weisnicht A, et al. What is the expected clearance of methotrexate? A therapeutic drug monitoring reference guide for high-dose methotrexate use in pediatric malignancies. Pediatr Blood Cancer. 2025;72(7):e31744. https:\/\/doi.org\/10.1002\/pbc.31744.","journal-title":"Pediatr Blood Cancer."},{"issue":"18","key":"1016_CR41","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.2169\/internalmedicine.4999-24","volume":"64","author":"M Akimoto","year":"2025","unstructured":"Akimoto M, Miyazaki T, Takahashi H, Takeda T, Hibino Y, Tokunaga M, et al. Delayed methotrexate elimination following high-dose methotrexate prophylaxis in high-risk diffuse large B-cell lymphoma. Intern Med. 2025;64(18):2716\u201322. https:\/\/doi.org\/10.2169\/internalmedicine.4999-24.","journal-title":"Intern Med."},{"issue":"10","key":"1016_CR42","first-page":"1100","volume":"27","author":"XB Lin","year":"2008","unstructured":"Lin XB, Zhou NN, Li S, Cai QQ, Xia ZJ, Liao H, et al. Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients. Ai Zheng. 2008;27(10):1100\u20135.","journal-title":"Ai Zheng."},{"issue":"10","key":"1016_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31213","volume":"71","author":"AN Chavana","year":"2024","unstructured":"Chavana AN, Taylor ZL, DeGroote N, Lindsay HB, Sauer HE, Mason EJ, et al. Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Pediatr Blood Cancer. 2024;71(10):e31213. https:\/\/doi.org\/10.1002\/pbc.31213.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"1016_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.31436\/jop.v5i2.343","volume":"5","author":"MN Yusoff","year":"2025","unstructured":"Yusoff MN, Mohamed Shah N, Mohd Tahir NA, Abdul Jabar SNN, Kori AN, Tumian NR. Predictors associated with delayed methotrexate clearance among patients with haematological malignancies. J Pharm. 2025;5(2):203\u201317. https:\/\/doi.org\/10.31436\/jop.v5i2.343.","journal-title":"J Pharm"},{"issue":"9","key":"1016_CR45","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403\u201310. https:\/\/doi.org\/10.1182\/blood-2014-10-604561.","journal-title":"Blood"},{"issue":"7","key":"1016_CR46","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/annonc\/mdh262","volume":"15","author":"S Smeland","year":"2004","unstructured":"Smeland S, Blystad AK, Kvaloy SO, Ikonomou IM, Delabie J, Kvalheim G, et al. Treatment of Burkitt\u2019s\/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol. 2004;15(7):1072\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdh262.","journal-title":"Ann Oncol."},{"issue":"1","key":"1016_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43046-022-00122-7","volume":"34","author":"S Barakat","year":"2022","unstructured":"Barakat S, Assem H, Salama M, Mikhael N, El Chazli Y. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia? J Egypt Natl Canc Inst. 2022;34(1):17. https:\/\/doi.org\/10.1186\/s43046-022-00122-7.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"12","key":"1016_CR48","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00277-016-2795-7","volume":"95","author":"SN Reiss","year":"2016","unstructured":"Reiss SN, Buie LW, Adel N, Goldman DA, Devlin SM, Douer D. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol. 2016;95(12):2009\u201315. https:\/\/doi.org\/10.1007\/s00277-016-2795-7.","journal-title":"Ann Hematol"},{"key":"1016_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2025.117436","volume":"502","author":"WY Lin","year":"2025","unstructured":"Lin WY, Tsai CK, Yeh CM, Liu CJ. Identifying risk factors for methotrexate-induced acute kidney injury despite full prevention in patients with primary central nervous system lymphoma. Toxicol Appl Pharmacol. 2025;502:117436. https:\/\/doi.org\/10.1016\/j.taap.2025.117436.","journal-title":"Toxicol Appl Pharmacol."},{"issue":"6","key":"1016_CR50","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00280-024-04713-0","volume":"94","author":"SR Christensen","year":"2024","unstructured":"Christensen SR, Jensen CF, Heldrup J, Taylor Z, Ramsey LB, Rosth\u00f8j S. Hypoalbuminemia in children with acute lymphoblastic leukemia: relation to asparaginase therapy and impact on high dose methotrexate elimination. Cancer Chemother Pharmacol. 2024;94(6):775\u201385. https:\/\/doi.org\/10.1007\/s00280-024-04713-0.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"12","key":"1016_CR51","doi-asserted-by":"publisher","first-page":"9566","DOI":"10.62347\/gdxh3501","volume":"17","author":"J Xu","year":"2025","unstructured":"Xu J, Huang G, Liu X, Zhao X, Chen X. Association between delayed methotrexate metabolism, coagulation function, and adverse reactions in patients with acute lymphoblastic leukemia receiving high-dose methotrexate treatment. Am J Transl Res. 2025;17(12):9566\u201379. https:\/\/doi.org\/10.62347\/gdxh3501.","journal-title":"Am J Transl Res."},{"key":"1016_CR52","unstructured":"Gounden V, Vashisht R, Jialal I. Hypoalbuminemia. https:\/\/www.statpearls.com\/point-of-care\/23253 (2026). Accessed 4\/1\/26 2026."},{"issue":"2","key":"1016_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jpen.1451","volume":"43","author":"PB Soeters","year":"2019","unstructured":"Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr. 2019;43(2):181\u201393. https:\/\/doi.org\/10.1002\/jpen.1451.","journal-title":"JPEN J Parenter Enteral Nutr."},{"issue":"3","key":"1016_CR54","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11739-012-0802-0","volume":"7","author":"A Gatta","year":"2012","unstructured":"Gatta A, Verardo A, Bolognesi M. Hypoalbuminemia. Int Emerg Med. 2012;7(3):193\u20139. https:\/\/doi.org\/10.1007\/s11739-012-0802-0.","journal-title":"Int Emerg Med."},{"key":"1016_CR55","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251340000","author":"M Vattaire-Herv\u00e9","year":"2025","unstructured":"Vattaire-Herv\u00e9 M, Le Bozec A, Clarenne J, Cohet G, Lepage V, Gossery C, et al. Predictive factors for delayed high-dose methotrexate elimination: a practical issue for diffuse large B-cell lymphoma patients. J Oncol Pharm Pract. 2025. https:\/\/doi.org\/10.1177\/10781552251340000. (Epub ahead of print).","journal-title":"J Oncol Pharm Pract."},{"issue":"1","key":"1016_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082681","volume":"9","author":"Y Liu","year":"2014","unstructured":"Liu Y, Yin Y, Sheng Q, Lu X, Wang F, Lin Z, et al. Association of ABCC2 \u2212\u00a024C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One. 2014;9(1):e82681. https:\/\/doi.org\/10.1371\/journal.pone.0082681.","journal-title":"PLoS One."},{"issue":"4","key":"1016_CR57","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/jpm14040440","volume":"14","author":"CL Choong","year":"2024","unstructured":"Choong CL, Islahudin F, Wong HS, Yahya R, Mohd Tahir NA, Makmor-Bakry M. The impact of ABCC2 \u2212\u00a024C>T gene polymorphism on graft survival in kidney transplant recipients. J Pers Med. 2024;14(4):440. https:\/\/doi.org\/10.3390\/jpm14040440.","journal-title":"J Pers Med."},{"issue":"3","key":"1016_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/08880018.2019.1705949","volume":"37","author":"RH Razali","year":"2020","unstructured":"Razali RH, Noorizhab MNF, Jamari H, James RJ, Teh KH, Ibrahim HM, et al. Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL). Pediatr Hematol Oncol. 2020;37(3):185\u201397. https:\/\/doi.org\/10.1080\/08880018.2019.1705949.","journal-title":"Pediatr Hematol Oncol."},{"issue":"5","key":"1016_CR59","doi-asserted-by":"publisher","first-page":"e1173","DOI":"10.1016\/j.clbc.2018.04.018","volume":"18","author":"RS Jabir","year":"2018","unstructured":"Jabir RS, Ho GF, Annuar M, Stanslas J. Association of allelic interaction of single nucleotide polymorphisms of influx and efflux transporters genes with nonhematologic adverse events of docetaxel in breast cancer patients. Clin Breast Cancer. 2018;18(5):e1173\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2018.04.018.","journal-title":"Clin Breast Cancer."},{"key":"1016_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2891-11-1","volume":"11","author":"SC Liew","year":"2012","unstructured":"Liew SC, Das-Gupta E, Wong SF, Lee N, Safdar N, Jamil A. Association of methylentetraydrofolate reductase (MTHFR) 677 C >\u00a0T gene polymorphism and homocysteine levels in psoriasis vulgaris patients from Malaysia: a case-control study. Nutr J. 2012;11:1. https:\/\/doi.org\/10.1186\/1475-2891-11-1.","journal-title":"Nutr J."},{"issue":"4","key":"1016_CR61","doi-asserted-by":"publisher","first-page":"186","DOI":"10.47102\/annals-acadmedsg.V40N4p186","volume":"40","author":"EH Mejia Mohamed","year":"2011","unstructured":"Mejia Mohamed EH, Tan KS, Ali JM, Mohamed Z. TT genotype of the methylenetetrahydrofolate reductase C677T polymorphism is an important determinant for homocysteine levels in multi-ethnic Malaysian ischaemic stroke patients. Ann Acad Med Singap. 2011;40(4):186\u201391.","journal-title":"Ann Acad Med Singap."},{"issue":"7","key":"1016_CR62","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/1354750x.2019.1648554","volume":"24","author":"SC Thambiah","year":"2019","unstructured":"Thambiah SC, Meor Anuar Shuhaili MFR, Chew BH, Samsudin IN, Abdul Rahman H, Stanslas J, et al. A pilot study on the association between SLCO1B1 RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort. Biomarkers. 2019;24(7):659\u201365. https:\/\/doi.org\/10.1080\/1354750x.2019.1648554.","journal-title":"Biomarkers."},{"key":"1016_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-026-00988-1","author":"C Massaux","year":"2026","unstructured":"Massaux C, Dogne JM, Musuamba FT. Differences in physiologically based pharmacokinetic predictions between software platforms can be clinically relevant: cases of levornestrogel and ethinylestradiol concentrations with SIMCYP versus PK-sim from a user perspective. Eur J Drug Metab Pharmacokinet. 2026. https:\/\/doi.org\/10.1007\/s13318-026-00988-1. (Epub ahead of print).","journal-title":"Eur J Drug Metab Pharmacokinet."},{"issue":"1","key":"1016_CR64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13317-017-0097-2","volume":"8","author":"L Cinquanta","year":"2017","unstructured":"Cinquanta L, Fontana DE, Bizzaro N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Auto Immun Highl. 2017;8(1):9. https:\/\/doi.org\/10.1007\/s13317-017-0097-2.","journal-title":"Auto Immun Highl."},{"issue":"5","key":"1016_CR65","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1515\/cclm-2015-0578","volume":"54","author":"V Gunther","year":"2016","unstructured":"Gunther V, Mueller D, von Eckardstein A, Saleh L. Head to head evaluation of the analytical performance of two commercial methotrexate immunoassays and comparison with liquid chromatography-mass spectrometry and the former fluorescence polarization immunoassay. Clin Chem Lab Med. 2016;54(5):823\u201331. https:\/\/doi.org\/10.1515\/cclm-2015-0578.","journal-title":"Clin Chem Lab Med."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01016-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:56:20Z","timestamp":1788980180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01016-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01016-y","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Chew Teng Keat reports having received consulting fees from Beigene, Pharmacy Essentia, and Novartis, and honoraria for lectures or educational activities from Novartis. He has also received support for meeting attendance or travel from Roche, Novo Nordisk, and Apotex. He serves in an unpaid role with the Malaysian Society of Haematology. All other relationships, activities, or interests relevant to this work have been disclosed, and the author declares no additional conflicts of interest. Other authors certify that they have no affiliations with or involvement in any organization or entity with any financial or nonfinancial interest in the subject matter or materials discussed in this manuscript.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approvals were obtained from the Medical Research and Ethics Committee (MREC) with approval number National Medical Research Register (NMRR) ID 24-00307-OET (IIR), the Research Ethics Committee of Universiti Kebangsaan Malaysia (JEPUKM) with approval number Jawatankuasa Etika Penyelidikan (JEP)-2024-1044, along with approval from the Clinical Research Center of each participating study site. The research was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. As this was a retrospective study using routinely collected clinical data obtained from the hospital electronic system, informed consent was not collected. Patient confidentiality was strictly maintained throughout the data collection and analysis process.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not involve any identifiable clinical photo of patient, or any identifiable patient data.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}